Aligos reports Q2 net loss $19.9M ($0.47), cash $159.3M, advances HBV/siRNA programs

Aligos Therapeutics, Inc.

2023-Q2 EPS reported -$1.30

Net loss $19.9M ($0.47/share) vs $29.8M ($0.79) in Q2 2021.
Cash & investments $159.3M at June 30, 2022 (down from $205.8M at Dec 31, 2021); funds ops into H1 2024.
R&D expenses decreased to $16.5M from $24.6M YoY, reflecting STOPS/ASO wind-down.
Completed enrollment in multiple CAM-2 and NASH Phase 1 cohorts; on track to file CTA for siRNA ALG-125755 in Q3 2022.
COVID-19 3CL PI ALG-097558 shows only 3-fold EC50 shift against resistant mutant vs >50-fold for nirmatrelvir.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.